NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Seamless Therapeutics

Seamless Therapeutics

Private
DresdenHealthcare & Life Scienceshttps://seamlesstx.com/

Last Round

Seed

Apr 23, 2024

Total Funding Raised

$37.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Seamless Therapeutics is a biotechnology company developing a gene-editing platform using programmable recombinases to create therapies for severe diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene editingrecombinase technologyprecision medicineDNA integrationgenetic medicinebiotech R&Dtherapeutic developmentgene therapymolecular engineeringbiotech licensinggenome engineeringCRISPR alternativesite-specific modificationdrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Seamless Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Seamless Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Seamless Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedApr 23, 2024
SeedMar 16, 2023

Key People

Founding team and executive leadership

Felix Lansing

Board Member, Chief Technology Officer, Co-Founder

Founding Team

Albert Seymour

President And CEO

Executive Team

Seamless Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 6, 2026

    Global agreement to develop treatments for hearing loss indications.

  • Jan 1, 2026

    Partnered to develop treatments for hearing loss in January 2026.

Seamless Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Seamless Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Seamless Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersDresden
Employee Range34
Year Founded2022
Last FundingApr 23, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.